Keeping Track Of Review Designations: BTDs For X4, F2G, And BMS; Another QIDP For Allergan
Executive Summary
The latest news about products accepted into US FDA expedited review programs.
You may also be interested in...
Keeping Track: A Good Week For Interstitial Lung Diseases; Opdivo+Yervoy Gains Liver Cancer Claim
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
March Madness: Upcoming US FDA Decision Dates To Watch
A dozen applications for new drugs and significant new indications are on the US FDA’s calendar of goal dates, including breakthrough-designated applications from Bristol-Myers Squibb and Boehringer Ingelheim.
Finance Watch: Big Money For Big Goals Met By Reata, CRISPR, Karuna
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.